We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.
Health conditions and diseases that the clinical trial is designed to study and treat.
A malignant solid tumor is a type of cancer that forms in solid organs or tissues, characterized by uncontrolled cell growth. Tumors associated with EphA2 expression can indicate a specific type of cancer that may require targeted therapies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
